RT Journal Article
SR Electronic
T1 Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 287
OP 291
DO 10.3949/ccjm.90a.22087
VO 90
IS 5
A1 Sanjoyita Mallick
A1 Gautam R. Shroff
A1 Mark Linzer
YR 2023
UL http://www.ccjm.org/content/90/5/287.abstract
AB The 2022 US Preventive Services Task Force (USPSTF) recommendation notes that the decision to initiate daily aspirin therapy for primary prevention of cardiovascular disease (CVD) should be made on a case-by-case basis for adults ages 40 to 59 with a 10% or greater 10-year CVD risk. The recommendation applies to those without signs or symptoms of clinically evident CVD who are not at an increased risk of bleeding. Clinicians are encouraged to use their judgment in weighing the risks and benefits of aspirin therapy, while taking patient preference into account for patients ages 40 to 60.